With Claimed Perfecting Feature In Contents (e.g., Excipient, Lubricant, Etc.) Patents (Class 424/465)
  • Patent number: 11020375
    Abstract: Disclosed is an Edaravone dosage form and a use thereof in preparing a drug used for treating diseases related to oxidative stress, the dosage form being selected from a lipid-based delivery system, a solid dispersion, micelles and a co-solvent based formulation.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: June 1, 2021
    Assignee: SUZHOU AUZONE BIOLOGICAL TECHNOLOGY CO., LTD.
    Inventors: Xinfu Zhou, Ankit Parikh, Sanjay Garg
  • Patent number: 11000520
    Abstract: The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: May 11, 2021
    Assignee: Indivior UK Limited
    Inventors: Azmi Nasser, Celine M Laffont, Christian Heidbreder
  • Patent number: 10988480
    Abstract: This invention relates to opioid ketal compounds of Formula (I), Formula (II), or Formula (III): or a pharmaceutically acceptable salts thereof, wherein R1 is H or CH3, R2 is H or OH, n is 0, 1, 2 or 3, R3 and R4 are independently H or optionally substituted C1-C4 alkyl, or when n is 0, then R3 and R4 and the carbon atoms to which they are attached together form six, or seven membered ring, which is optionally mono or disubstituted by C1-C4 alkyl. The invention also relates to oxycodone ketal compounds of Formula (IV) or (V): or a pharmaceutically acceptable salts thereof. The invention also relates to the use of such compounds for the treatment, prevention, or amelioration of pain.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: April 27, 2021
    Assignee: Rhodes Technologies
    Inventors: Robert J. Kupper, Raymond C. Glowaky
  • Patent number: 10966928
    Abstract: The present invention in general relates to a pharmaceutical dosage form comprising one or more granules, and a method for manufacturing thereof. The granules of the dosage form are prepared via the extrusion/spheronization technique using partially hydrolysed polyvinyl alcohol. These granules have the advantage that a high drug load can be contained therein.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: April 6, 2021
    Assignee: Universiteit Gent
    Inventors: Chris Vervaet, Jean Paul Remon, Glenn Verstraete
  • Patent number: 10966964
    Abstract: The present invention provides a method for preparing a pharmaceutical composition containing a pyrrolo-fused six-membered heterocyclic compound or a pharmaceutically acceptable salt thereof. Specifically, the invention provides a preparation method of a pharmaceutical composition, the method containing: mixing 5-(2-diethylamino-ethyl)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidene-methyl)-3-methyl-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one or a pharmaceutically acceptable salt thereof with at least one filler, and then granulating the mixture. The pharmaceutical composition of the invention features a rapid dissolution and good stability.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: April 6, 2021
    Assignee: Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Yun Lu, Xinhua Zhang, Chenyang Wang, Tonghui Liu
  • Patent number: 10960015
    Abstract: Provided is a fast-dissolving effervescent pharmaceutical formulation of pyridoxal-5-phosphate, and to the use thereof in the treatment of neonatal epilepsy and also of metabolic disorders with a need for pyridoxal-5-phosphate.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: March 30, 2021
    Assignee: Assistance Publique-Hopitaux De Paris
    Inventors: Stéphane Auvin, Thomas Storme, Pascal Vaconsin, Vincent Boudy
  • Patent number: 10918604
    Abstract: The present invention relates to high drug load pharmaceutical compositions comprising Eslicarbazepine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof. The present invention also relates to a process for preparing high drug load solid oral pharmaceutical composition comprising Eslicarbazepine acetate and at least one pharmaceutically acceptable excipient. The prior art highlights various technical challenges for formulation development of Eslicarbazepine acetate at lab as well as at industrial scale and offer restrictive and complex approach for resolution of technical challenges. Compositions of Eslicarbazepine acetate prepared as per present invention, wherein disintegrant and/or binder is present in either intra-granular part or in extra-granular part of the composition exhibited desirable technical attributes like comparable dissolution and bioequivalence against reference listed drug.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: February 16, 2021
    Inventors: Ravikumar Nithiyanandam, Ganesh Vinayak Gat, Dinesh Kumar, Kamal S. Mehta, Premchand Dalichandji Nakhat, Vivek Jain, Priyank Sharma, Baibhav Joshi
  • Patent number: 10888519
    Abstract: The present invention relates to a stable, immediate release solid oral pharmaceutical compositions comprising iron chelating agents like Deferasirox and at least one pharmaceutical acceptable excipient wherein the composition is free of glidant. Prior art discloses various technical challenges and suggest restrictive and complex solutions for the development of immediate release dosage forms of Deferasirox such as utilizing a large number of excipients or non-conventional formulation techniques. The glidant free immediate release solid oral pharmaceutical composition of Deferasirox, prepared as per present invention exhibited desirable technical attributes like pharmaceutical stability, flow properties and comparable dissolution, bioequivalence against reference listed drug.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: January 12, 2021
    Inventors: Pankaj Soni, Premchand Dalichandji Nakhat, Ganesh Vinayak Gat, Kamal S. Mehta, Dinesh Kumar, Vikas Bali
  • Patent number: 10869839
    Abstract: The present disclosure provides extended release trihexyphenidyl compositions suitable for once- or twice-daily administration. The compositions comprise a core comprising organic acid that is coated with at least one drug layer comprising trihexyphenidyl hydrochloride, and a functional coat over the drug-layered core. The extended release compositions of the disclosure provide reduced Cmax, a Cmin:Cmax ratio of ?0.4, and extended release, while maintaining therapeutically effective concentration, of trihexyphenidyl for at least about 16 hours. The compositions of the disclosure improve solubility of trihexyphenidyl hydrochloride, at a pH of greater than or equal to 5, to maintain its minimum effective concentration at such pH.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: December 22, 2020
    Assignee: KASHIV BIOSCIENCES, LLC
    Inventors: Namdev B. Shelke, Siva Ram Kiran- Vaka, Navnit H. Shah, Dipen Desai, Wantanee Phuapradit
  • Patent number: 10842760
    Abstract: A sustained-release preparation containing pseudoephedrine is provided comprising pseudoephedrine or a pharmaceutically acceptable salt thereof, and a hardened oil or stearic acid. The sustained-release preparation containing pseudoephedrine may contain a hardened oil or stearic acid in an amount of 100% by mass to 500% by mass with respect to the content of the pseudoephedrine or a pharmaceutically acceptable salt thereof. In addition, the sustained-release preparation containing pseudoephedrine may have a first part and a second part, the first part may contain the pseudoephedrine or a pharmaceutically acceptable salt thereof, and the first part or the second part may contain an optional active ingredient.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: November 24, 2020
    Assignee: SAWAI PHARMACEUTICAL CO., LTD.
    Inventors: Yuki Nishikawa, Hiroaki Kikuoka, Michinori Oikawa, Hiroyuki Yamamoto, Tomoya Nakagawa
  • Patent number: 10842750
    Abstract: The invention relates to a pharmaceutical dosage form which is particularly useful for the prevention of an overdose of the pharmacologically active ingredient contained therein after accidental or intentional simultaneous administration of a plurality of the dosage forms containing an overall supratherapeutic dose of the pharmacologically active ingredient.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: November 24, 2020
    Assignee: GRÜNENTHAL GMBH
    Inventors: Klaus Wening, Sebastian Schwier, Ulrike Bertram
  • Patent number: 10786489
    Abstract: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: September 29, 2020
    Assignee: Loxo Oncology Inc.
    Inventors: Mark Reynolds, Charles Todd Eary
  • Patent number: 10751272
    Abstract: Disclosed is a method of preparing a product composition comprising steps of: Preparing a mixture composition comprising a surfactant and a high melting point fatty compound and benefit agent; Separately preparing an aqueous base composition comprising an aqueous carrier and water soluble polymer, wherein the base composition is substantially free of a detersive surfactant selected from anionic surfactants, zwitterionic surfactant, amphoteric surfactant, and combinations thereof; Mixing the mixture composition and the aqueous base composition to form a discrete particle of the mixture composition dispersed in the aqueous base composition. Alternatively, the method comprises steps of preparing a discrete particle of the mixture composition; and mixing it with the aqueous composition.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: August 25, 2020
    Assignee: The Procter and Gamble Company
    Inventors: Junichi Yokogi, XinHao Zhu, Jorge Max Sunkel
  • Patent number: 10736909
    Abstract: The present disclosure discloses trehalose for use in treatment of neurological disorders, wherein the trehalose is for a single daily administration with the daily dose between about 0.25 to about 12.5 g/kg/day. The daily dose may be about 2.67 g/kg/day. A method for treating a neurological disorders is disclosed which involves administering trehalose to a subject as a single daily administration with a daily dose between about 0.25 to about 12.5 g/kg/day and in an embodiment of this method the daily dose is about 2.67 g/kg/day. Also disclosed herein is the use of trehalose in the manufacture of a medicament for treatment of neurological disorders, wherein the trehalose is formulated as a single daily dose with the trehalose present in the medicament in an amount of between about 0.25 to about 12.5 g/kg/day. In an embodiment the daily dose is about 2.67 g/kg/day.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: August 11, 2020
    Assignee: JUNAXO, INC.
    Inventors: Jonathan Michael Brotchie, Patrick Alexander Howson
  • Patent number: 10729653
    Abstract: The present invention relates to an immediate release formulation of pharmaceutical compounds.
    Type: Grant
    Filed: January 27, 2010
    Date of Patent: August 4, 2020
    Assignee: UCB BIOPHARMA SRL
    Inventors: Serge Cuypers, Monique Berwaer, Domenico Fanara, Valery Barillaro
  • Patent number: 10695297
    Abstract: The invention relates to a tamper-resistant tablet comprising (i) a matrix material in an amount of more than one third of the total weight of the tablet; and (ii) a plurality of particulates in an amount of less than two thirds of the total weight of the tablet; wherein said particulates comprise a pharmacologically active compound and a polyalkylene oxide; and form a discontinuous phase within the matrix material; and method of using said tablet to treat pain and other conditions.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: June 30, 2020
    Assignee: GRÜNENTHAL GMBH
    Inventors: Sebastian Schwier, Marcel Haupts, Udo Rüttgers, Lutz Barnscheid, Jana Denker
  • Patent number: 10688053
    Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: June 23, 2020
    Assignee: INSPIRION DELIVERY SCIENCES, LLC
    Inventors: Manish S. Shah, Ray Difalco
  • Patent number: 10668156
    Abstract: Described are solid dispersions of hydrophobic active ingredients and cationic copolymers of N,N-diethylaminoethyl methacrylate and methyl methacrylate in a weight ratio of the monomers of from 35:65 to 55:45. Also described are the preparation and use of such solid dispersions for pharmaceutical dosage forms.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: June 2, 2020
    Assignee: BASF SE
    Inventors: Karl Kolter, Maximilian Angel, Matthias Karl, Silke Gebert, Michael Klemens Mueller
  • Patent number: 10668016
    Abstract: The present disclosure relates to pharmaceutically acceptable complex formulae comprising complexes of Abiraterone acetate and pharmaceutically acceptable excipients, process for the preparation thereof and pharmaceutical compositions containing them. The complex formulae of the present disclosure have improved physicochemical properties which results in reduced food effect which allows significant dose reduction and the abandoning of the requirement of taking the drug on an empty stomach.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: June 2, 2020
    Assignee: NanGenex Nanotechnology Incorporated
    Inventors: Réka Angi, Tamás Jordán, Orsolya Basa-Dénes, Tamás Solymosi, Zsolt Ötvös, Hristos Glavinas, Genovéva Filipcsei
  • Patent number: 10668021
    Abstract: Provided are a metformin hydrochloride osmotic pump tablet and a preparation method therefor. According to the preparation method, a hetero-type stamping-prepared metformin hydrochloride tablet core is used, and a controlled-release coating is wrapped outside the stamped metformin hydrochloride tablet core, such that the metformin hydrochloride osmotic pump tablet is prepared.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: June 2, 2020
    Assignee: ELITE PHARMA TECHNOLOGY (SHANGHAI) CO., LTD.
    Inventors: Wu Tian, Qing Tian, Jianping Jiang
  • Patent number: 10653663
    Abstract: Provided is a pharmaceutical composition for oral administration, including (a) a taxane, (b) a medium chain triglyceride, (c) an oleoyl glycerol complex having 30 to 65% by weight of monooleoyl glycerol contents; 15 to 50% by weight of dioleoyl glycerol contents; and 2 to 20% by weight of trioleoyl glycerol contents, (d) a surfactant, and optionally (e) polyoxyl glyceryl fatty acid ester and a process for preparing the same.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: May 19, 2020
    Assignee: DAE HWA PHARMA. CO., LTD.
    Inventors: In-Hyun Lee, Min-Hee Son, Yeong-Taek Park, Seul-Ae Lee, Han-Koo Lee
  • Patent number: 10646447
    Abstract: The present invention relates to an oral sustained-release triple layer tablet, more particularly, a triple layer tablet consisting of an inner immediate-release layer containing a pharmaceutically active ingredient and two outer layers containing swellable polymers. Upon exposure to aqueous media, the two outer layers swell to form gelled layers surrounding the lateral side of the inner layer rapidly, thereby control effectively the release of the pharmaceutically active ingredient from the inner immediate-release layer.
    Type: Grant
    Filed: February 11, 2008
    Date of Patent: May 12, 2020
    Assignee: GL PHARMTECH CORP.
    Inventors: Jun Sang Park, U-Hun Song, Ji-Yeon Sim
  • Patent number: 10639340
    Abstract: A method for drying to increase the useful life of botanicals and shorten the time to market after harvest of the botanicals. The method may include flash freezing the botanicals, at a desired optimal temperature range, soon after harvest. The method may include storing the frozen botanicals indefinitely prior to drying. The method may include drying the frozen botanicals using a lyophilizer at a desired optimal temperature and pressure.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: May 5, 2020
    Inventor: Eric Young
  • Patent number: 10638778
    Abstract: A method for producing powderized cannabis oil, and the resulting powderized cannabis oil, in which concentrated cannabis oil is mixed with and absorbed by a modified starch powder, preferably maltodextrin, in a ratio of at least three grams of starch powder for every one-eighth of a gram of cannabis oil is disclosed. Further disclosed are beverages, baked goods and single-serve beverage brewing cartridges utilizing or incorporating the powderized cannabis oil to create human-consumable products that contain an emulsified, tasteless, and odorless dose of cannabis oil.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: May 5, 2020
    Assignee: Pivot Pharmaceuticals US Inc.
    Inventors: Ross M. Franklin, Ed Rosenthal, Rachel M. Franklin
  • Patent number: 10624888
    Abstract: Extended release, abuse deterrent dosage forms comprising crush-resistant controlled-release particles that provide abuse deterrent properties to the dosage forms. The crush-resistant controlled-release particles, which comprise plastic/elastic polymers and at least one active pharmaceutical ingredient (API) or a pharmaceutically acceptable salt thereof, are prepared by a hot melt extrusion process.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: April 21, 2020
    Assignee: SpecGX LLC
    Inventors: Jonathan Gaik, Jaehan Park, Ryan Lathrop, Gary Nichols, John Schallom
  • Patent number: 10603279
    Abstract: The present invention relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug lopinavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: March 31, 2020
    Assignee: The University of Liverpool
    Inventors: Marco Norman Giardiello, Thomas Oliver McDonald, Andrew Owen, Steven Paul Rannard, Philip John Martin, Darren Lee Smith, James Long
  • Patent number: 10603312
    Abstract: The invention pertains to methods that include administering to a subject a transoral dosage form comprising a pharmaceutical carrier and sufentanil, and maintaining a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test. Related dosage forms are also disclosed. Also disclosed are transoral dosage forms and related methods, wherein a transoral dosage form may comprise: (1) about 5 to about 1000 micrograms of sufentanil; (2) about 50 micrograms to about 100 milligrams of naloxone; and (3) acidifying material in an amount sufficient to provide a mean pH ranging from about 3.5 to about 5.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: March 31, 2020
    Assignee: Durect Corporation
    Inventors: Su Il Yum, Jaymin Shah, Sung Yun Kwon, Xiaoping Song
  • Patent number: 10596119
    Abstract: Disclosed herein are treatments for diseases such as sleep apnea, hyperuricemia, autistic spectrum disorder (ASD) and other brain disorders using controlled-release (CR, e.g., extended-release (ER) or prolonged-release (PR)) oral dosage formulations comprising an effective amount of Torsemide.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: March 24, 2020
    Inventor: Salim Shah
  • Patent number: 10568841
    Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: February 25, 2020
    Assignee: PURDUE PHARMA L.P.
    Inventors: Ricardo Alberto Vargas Rincon, Joseph Reiz
  • Patent number: 10561618
    Abstract: The present invention provides a pharmaceutical formulation for oral administration comprising an agonist of two or more of the 5-HT1B, 5-HT1D and 5-HT1F receptors, such as a triptan, e.g. zolmitriptan, in a matrix constituent with extended release characteristics, and further comprising a 5-HT1A-R agonist, such as buspirone, in a constituent with immediate-release characteristics. The special formulation is particularly well-suited for use in the treatment of movement disorders by combining the two active ingredients in a manner that achieves synergy from both the combination per se and the special release parameters of the pharmaceutical formulation, allowing for ease of administration and reducing the risk of adverse effects of each of the two active ingredients.
    Type: Grant
    Filed: April 18, 2013
    Date of Patent: February 18, 2020
    Assignee: Contera Pharma ApS
    Inventors: John Bondo Hansen, Mikael S. Thomsen, Jens D. Mikkelsen, Peter Gudmund Nielsen, Mads Kreilgaard
  • Patent number: 10555906
    Abstract: Provided are solid oral/per os formulations that include a single cannabinoid, combination of cannabinoids, cannabis extract and combination of cannabis plant constituents. Also provided are methods of making the formulations, as well as therapeutic applications in the treatment and alleviation of various human disorders and/or conditions.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: February 11, 2020
    Assignees: GELPELL AG, SATIPHARM AG
    Inventors: Hagit Sacks, Tomas Edvinsson
  • Patent number: 10537583
    Abstract: An oral formulation, and preparation method and use thereof; the oral formulation comprises 1-50 parts by weight of an A-nor-5a-androstane compound, 20-95 parts by weight of a filling agent, 0-20 parts by weight of a disintegrant, 0.1-30 parts by weight of a binder, 0.1-5 parts by weight of a lubricant and 0.1-5 parts by weight of a glidant. The oral formulation has a high stability and a good dissolution performance.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: January 21, 2020
    Inventor: Yajun Chen
  • Patent number: 10525059
    Abstract: The present invention relates to a tablet comprising Afatinib or a pharmaceutically acceptable salt thereof, wherein the tablet is obtained by direct compression. The present invention further relates to a process for manufacturing a tablet of the invention as well as the use of the tablet of the invention.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: January 7, 2020
    Assignee: Fresenius Kabi Oncology, Ltd.
    Inventors: Rajesh Khanna, Neeraj Kumar, Vijay Kumar Sharma, Ankit Gaur, Dhiraj Khattar
  • Patent number: 10517829
    Abstract: The present invention provides extended release pharmaceutical compositions structured for once a day administration comprising skeletal muscle relaxant such as cyclobenzaprine or its pharmaceutically acceptable salt thereof that extends the release of the drug under in-vitro conditions for at least 8 to 12 hours. The invention also provides process for the preparation of such structured compositions.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: December 31, 2019
    Assignee: INVENTIA HEALTHCARE LIMITED
    Inventors: Sunil Beharilal Jaiswal, Vaibhavi Ankur Shah, Sunil Deviprasad Tiwari
  • Patent number: 10507180
    Abstract: Compositions, systems and methods for administration of small volume sufentanil drug dosage forms to the sublingual mucosa of a subject for treatment of pain using a device are disclosed.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: December 17, 2019
    Assignee: AcelRx Pharmaceuticals, Inc.
    Inventors: Pamela Palmer, Thomas Schreck, Stelios Tzannis, Larry Hamel, Andrew I. Poutiatine
  • Patent number: 10493035
    Abstract: Provided herein are high strength/high drug load tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (“Compound 1”), dispersible tablets comprising Compound 1, processes of manufacturing such tablets, and methods for treating patients with the tablets. Compound 1 is useful for treating hematological disorders such as sickle cell disease, pulmonary disease such as idiopathic pulmonary fibrosis, and hypoxia and hypoxemia conditions.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: December 3, 2019
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Sean Mark Dalziel, Naveen Bejugam, Nazila Habibizad, Ali Komeyli, DeMei Leung
  • Patent number: 10478413
    Abstract: The present invention relates to a high adhesion dermal therapeutic system comprising an adhesive polymeric matrix with a salt of Diclofenac.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: November 19, 2019
    Assignee: FIDIA FARMACEUTICI S.P.A.
    Inventors: Giovanni Gennari, Anna Maria Zanellato, Patrizia Santi, Cristina Padula
  • Patent number: 10471056
    Abstract: The invention relates to a dosage form that is suitable for releasing an active ingredient over a long period of time. For this purpose, the active ingredient is released in two-stages in order to do away with an excessively frequent ingestion of the dosage form. The dosage forms according to the invention are for treating dizziness in humans. They are administered with or after a meal. The concept according to the invention provides that the pharmaceutical form has a dimensionally stable portion which, after ingestion of the dosage form by the patients, does not dissolve in the chyme-filled stomach for a number of hours. In this way, this dimensionally stable portion remains in the stomach until same is evacuated by the so-called “housekeeper waves”. Another portion of the dosage form is formed in such a way that it dissolves within a short time of the patients ingesting same. In this way, a quick invasion of the active ingredient with corresponding plasma levels is ensured.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: November 12, 2019
    Assignee: HENNIG ARZNEIMITTEL GMBH & CO. KG
    Inventors: Jan Christoph Grewe, Karl-Heinz Przyklenk
  • Patent number: 10463623
    Abstract: The present invention provides a composition exhibiting delayed transit through the gastrointestinal tract comprising one or more active agents, fenugreek fiber and at least one pharmaceutically acceptable excipient. The present invention further relates to gastroretentive dosage forms comprising fenugreek fibers.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: November 5, 2019
    Assignee: RUBICON RESEARCH PRIVATE LIMITED
    Inventors: Pratibha Sudhir Pilgaonkar, Maharukh Tehmasp Rustomjee, Anilkumar Surendrakumar Gandhi, Rupali Kedar Suvarnapathaki
  • Patent number: 10434067
    Abstract: Provided are a solid composite formulation for oral administration, the solid composite formulation including: an ezetimibe granules-part including ezetimibe, said ezetimibe having a particle size distribution wherein the average particle size d(0.9) for the bottom 90% is about 10 ?m or less; and a rosuvastatin mixture-part including rosuvastatin or a pharmaceutically acceptable salt thereof, and a method of preparing the composite formulation.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: October 8, 2019
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Jung Hyun Cho, Jin Cheul Kim, Yong Il Kim, Seung Jun Lee, Jae Hyun Park, Jong Soo Woo
  • Patent number: 10406105
    Abstract: Pharmaceutical formulation in the form of agglomerates comprising A) an excipient content composed of a) 60-97% by weight of sugar or sugar alcohols, b) 1-25% by weight of a disintegrant, c) 1-15% by weight of water-insoluble, film-forming polymers d) 0-15% by weight of water-soluble polymers and e) 0-15% by weight of further pharmaceutically customary excipients the total of the components a) to e) being 100% by weight, and B) at least one active ingredient.
    Type: Grant
    Filed: June 3, 2008
    Date of Patent: September 10, 2019
    Assignee: BASF SE
    Inventors: Karl Kolter, Michael Schönherr, Silke Gebert, Kathrin Meyer-Böhm, Angelika Maschke
  • Patent number: 10391103
    Abstract: Disclosed are a ferroporphyrin solid dispersion, preparation method therefor and a pharmaceutical composition comprising the solid dispersion, wherein the weight ratio of ferroporphyrin to the carrier material in the dispersion is 1:1-1:10. The solid dispersion of the present invention masks the undesirable taste of ferroporphyrin, ameliorates irritation thereof to the digestive tract, and at the same time increases the solubility thereof and improves the bioavailability thereof.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: August 27, 2019
    Assignee: SINOTHERAPEUTICS INC.
    Inventors: Larry Yun Fang, Jiansheng Wan, Kun Li, Maojian Gu
  • Patent number: 10369108
    Abstract: The presently disclosed subject matter is directed to a granule, wherein the granule has an active agent and a wax dispersed therein, and the granule exhibits excellent friability when compressed to form a pharmaceutical composition. The subject matter disclosed herein is also directed to methods of preparing the granules and the pharmaceutical compositions comprising the granules. The compositions and methods disclosed provide granules and pharmaceutical compositions for immediate release of the active agent and do not substantially prolong the release of the active agent from the granule.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 6, 2019
    Assignee: Mylan Laboratories, Inc.
    Inventors: Chaoju Xiao, Boyong Li
  • Patent number: 10328029
    Abstract: The present invention relates to oral pharmaceutical compositions comprising nitisinone, or a pharmaceutically acceptable salt thereof, their use in the treatment of tyrosinemia, such as Hereditary Tyrosinemia type-1 (HT-1), or alkaptonuria. The compositions have improved stability characteristics. The invention also relates to processes for producing nitisinone.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: June 25, 2019
    Assignee: CYCLE PHARMACEUTICALS LTD
    Inventors: James Harrison, Stephen Fuller, Tobias Josef Brown
  • Patent number: 10323226
    Abstract: A bacteria starter material for use in biomass generators without causing jamming of the feeder mechanism, particularly under high temperature and/or high humidity conditions, the starter material comprising one or more species of waste-decomposing bacteria, sucrose, and a soy based protein. Preferably, DI-PAC® sugar (sucrose and maltodextrin) and powdered KIKKOMAN® Soy Sauce are used as the sugar and protein ingredients. The starter material may also comprise a dried bran culture comprising Pseudomonas. The starter material ingredients are blended together and formed into a tablet or pellet having a particular shape, size, and hardness characteristics suitable for use in the feeder mechanism of a biomass generator.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: June 18, 2019
    Assignee: NCH Corporation
    Inventors: Judith G. Pruitt, Robert C. Pearce, III, Daniel Aberle, Charles J. Greenwald, Gabriel F. K. Everett
  • Patent number: 10323056
    Abstract: The present invention relates to non-stoichiometric crystalline hydrates of 1-(?-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene, processes for their preparation, and their use as medicaments. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel crystalline hydrates.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: June 18, 2019
    Assignee: Lek Pharmaceuticals d.d.
    Inventors: Lovro Selic, Andreas Hotter, Christoph Langes, Ulrich Griesser
  • Patent number: 10314788
    Abstract: An oral pharmaceutical composition comprising a drug and one or more pharmaceutically acceptable excipients in a monolithic dosage form, wherein the dosage form is configured such that when the dosage form is divided into more than one piece and at least one of the pieces is administered to a subject the Cmax, AUC, and/or rate of drug released after administration is substantially the same or lower and the Tmax is higher than the Cmax, AUC, rate of drug released, and/or Tmax after administration of: (1) a comparable composition in intact dosage form of equal drug dosage of the administered at least one piece; (2) a bioequivalent drug composition in an intact dosage form of equal drug dosage to the administered at least one piece; and (3) a divided piece of a bioequivalent drug composition, wherein the divided piece comprises a drug dosage equal to the dosage of the administered piece of the oral composition. Methods of making the same and methods of using the same are also provided.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: June 11, 2019
    Assignee: INSPIRION DELIVERY SCIENCES LLC
    Inventors: Manish S. Shah, Ray J. Difalco
  • Patent number: 10292966
    Abstract: The present invention provides controlled release dosage formulations of compounds having the Formula: or pharmaceutically acceptable salts thereof, and in particular, aplindore. The dosage forms are useful, inter alia, for reducing side effects from administration of such compounds.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: May 21, 2019
    Assignee: Wyeth LLC
    Inventors: Eric J. Benjamin, Wendy A. Dulin, Yanning Lin, Kai Zhuang
  • Patent number: 10271551
    Abstract: A wiping composition and a wiping product containing the composition are disclosed. The wiping composition contains a combination of an antimicrobial agent with a preservative enhancing agent that not only provides antiseptic properties when applied to an adjacent surface, but also is well suited to preserving the substrate that is used to apply the composition. In particular, the composition has been unexpectedly found to inhibit or destroy bacteria, particularly Burkholderia cepacia, even when the active ingredients are used at extremely low levels.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: April 30, 2019
    Assignee: Lonza Inc.
    Inventors: Angela Marie Sangirardi, Susan Ahrendt Mills, Vito Thomas Cataldo
  • Patent number: 10265301
    Abstract: The disclosure provides for improved pharmaceutical compositions containing deferasirox (DFX) and methods of manufacturing the same. In particular, the compositions are prepared using thermokinetic compounding and provide improved properties as well as more efficient methods of manufacture.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: April 23, 2019
    Assignee: DISPERSOL TECHNOLOGIES, LLC
    Inventors: Dave A. Miller, Justin M. Keen, Sandra U. Kucera